Name

AD

Alternate names

ADIC

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for AD

Name

Alternate Names

Deticene
Detimedac
Dimethyl-triazeno-imidazole-carboxamide
DTIC-Dome
Fauldetic
Imidazole carboxamide
WR-139007

Abbreviations

DIC
DTIC
ICDT
ICT

Category

Chemotherapy

Subcategory

Antimetabolite
Nonclassic alkylating agent

NSC Number

45388
045388

Primary Site

Hodgkin's disease
melanoma
Neuroblastoma
Soft tissue sarcomas

Histology

None

Remarks

FDA approved on Hodgkin's lymphoma, and metastatic melanoma.

Coding

This drug should be coded

Name

Alternate Names

14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin

Abbreviations

ADM
ADR
ADRI

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

123127

Primary Site

Bladder
breast
liver
multiple myeloma
ovarian
pancreatic
prostate cancer

Histology

None

Remarks

Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic

Coding

This drug should be coded
Glossary